William Baumgartner  |  10/30/2009 1:16:18 AM

TransGenRx, a biopharmaceutical manufacturing company, has developed technology that significantly reduces the cost of producing protein-based drugs by using a high-expressing avian cell line combined with their patented vector system. Patented and patent pending processes allow TGRx to develop custom proteins to meet a wide range of specifications. Dr. Richard Cooper, a professor in the AgCenter Department of Veterinary Science, serves as the company's Executive Vice President of Research and Development. Since its inception, the company has won an STTR phase II award and has won contracts with drug manufacturers for its proteins and hormones.

June 6, 2003
LSU AgCenter Announces Biotechnology Breakthrough

August 2005
TGRx Wins 2005 ‘Quality Award’ from U.S. Army 

October 28, 2009
TransGenRx gets $30 million contract with Argentinean company

February 9, 2012
TransGenRx signs agreement with Novocyt

To find more information about TransGenRx, visit:
Rate This Article:

Have a question or comment about the information on this page?

Innovate . Educate . Improve Lives

The LSU AgCenter and the LSU College of Agriculture